Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 12;16(12):2757-2759.
doi: 10.1093/ckj/sfad230. eCollection 2023 Dec.

Neutralizing response against SARS-CoV-2 Omicron BA.5 and XBB.1.5 in hemodialysis patients

Patrick Affeldt  1   2   3 , Karl August Brensing  4 , Eva Heger  2 , Maike Wirtz  2 , Gertrud Steger  2 , Felix Carlo Koehler  1   5 , Thomas Benzing  1   5 , Dirk Stippel  6 , Florian Klein  2   3 , Christine Kurschat  1   5 , Roman-Ulrich Müller  1   5 , Veronica Di Cristanziano  2
Affiliations

Neutralizing response against SARS-CoV-2 Omicron BA.5 and XBB.1.5 in hemodialysis patients

Patrick Affeldt et al. Clin Kidney J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

F.K. is listed as inventor on patent application on SARS-CoV-2 neutralizing antibodies filed by the University of Cologne. The other authors have no conflicts of interest to declare.

Figures

Figure 1:
Figure 1:
Serum neutralizing activity against SARS-CoV-2 Omicron BA.5 and XBB.1.5 in hemodialysis patients (HD) with different immunization schemes. (A) Pie chart of patients with neutralizing activity ≥ 1:250 or < 1:250 and different immunization schemes (inner circle BA.5, outer circle XBB.1.5, transparent bar: neutralizing activity titers <1:250, solid bars: neutralizing activity ≥1:250, numbers in bars: number of patients). Group 1: patients after four doses of monovalent mRNA vaccination (Moderna or BioNTech) and one dose of bivalent BA.4/5 adapted mRNA vaccination; Group 2: patients after four doses of monovalent mRNA vaccination (Moderna or BioNTech) and one dose of bivalent BA.1-adapted vaccination; Group 3: patients after three or four doses of monovalent mRNA vaccination (Moderna or BioNTech); Group 4: patients after three doses of monovalent mRNA vaccination (Moderna or BioNTech), Omicron breakthrough infection and additional mRNA booster vaccination with bivalent BA.4/5 vaccine; Group 5: patients after Omicron breakthrough infection and three or four doses of monovalent mRNA vaccination (Moderna or BioNTech); (B) Heat map of anti-RBD (receptor binding domain) titers and neutralizing activity against Omicron BA.5 and XBB.1.5. Each line represents one patient. For anti-RBD IgG titers color ranged from red = 0 to yellow = 1250 and green >12 500 BAU/ml. For neutralizing activity titers color ranged from red = 0, to yellow ≥1:250, to green ≥1:2500. Numbers in black and white boxes to the right represent the different immunization schemes, as reported above. NT, neutralization assay.
See this image and copyright information in PMC

References

    1. Collie S, Nayager J, Bamford Let al. . Effectiveness and durability of the BNT162b2 vaccine against Omicron sublineages in South Africa. N Engl J Med 2022;387:1332–3. 10.1056/NEJMc2210093 - DOI - PMC - PubMed
    1. He C, Alu A, Lei Het al. . A recombinant spike-XBB.1.5 protein vaccine induces broad-spectrum immune responses against XBB.1.5-included Omicron variants of SARS-CoV-2. MedComm 2023;4:e263. 10.1002/mco2.263 - DOI - PMC - PubMed
    1. Platen L, Liao B-H, Tellenbach Met al. . Longitudinal SARS-CoV-2 neutralization of Omicron BA.1, BA.5 and BQ.1.1 after four vaccinations and the impact of breakthrough infections in haemodialysis patients. Clin Kidney J 2023; 10.1093/ckj/sfad147 - DOI - PMC - PubMed
    1. Affeldt P, Koehler FC, Brensing KAet al. . Immune response to third and fourth COVID-19 vaccination in hemodialysis patients and kidney transplant recipients. Viruses 2022;14:2646. 10.3390/v14122646 - DOI - PMC - PubMed
    1. Feng S, Phillips DJ, White Tet al. . Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med 2021;27:2032–40. 10.1038/s41591-021-01540-1 - DOI - PMC - PubMed